Conference
PCV25 Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions
Authors
Haddad P; McKelvie R
Volume
20
Publisher
Elsevier
Publication Date
October 1, 2017
DOI
10.1016/j.jval.2017.08.1170
Conference proceedings
Value in Health
Issue
9
ISSN
1098-3015